AlphaFold predicted structure
MAN2B2 · Q9Y2E5

Mean pLDDT
91.1/ 100
Very high
1,009 residues
Confidence breakdown
- Very high(≥ 90)83%
- Confident(70–90)8%
- Low(50–70)4%
- Very low(< 50)5%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
mannosidase alpha class 2B member 2
Annotations refreshed 9 hours ago.
Diagnostic Grade (Green)
Congenital disorders of glycosylation
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalPrimary immunodeficiency or monogenic inflammatory bowel disease
BIALLELIC, autosomal or pseudoautosomalcongenital disorder of glycosylation type 1EE with or without immunodeficiency
blood coagulation disease
malignant renal pelvis neoplasm
placental abruption
gastric cancer
congenital disorder of glycosylation
transient neonatal diabetes mellitus
diabetes mellitus, transient neonatal, 3
MODY
maturity-onset diabetes of the young type 13
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Epididymis-specific alpha-mannosidase
Specifically cleaves terminal alpha 1,6-linked mannose residues on Man3GlcNAc and Man2GlcNAc core oligosaccharides generated by N-glycan degradation pathways, having little activity, if any, on larger mannose oligosaccharides (PubMed:1577805, PubMed:16115860). Does not cleave terminal alpha 1,6-linked mannose on Man3GlcNAc2, and is also unable to hydrolyze terminal alpha 1,3-mannose linkages (PubMed:1577805, PubMed:16115860)
MAN2B2 · Q9Y2E5

Mean pLDDT
91.1/ 100
Very high
1,009 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0